RecruitingNCT06073470

Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

Exploration of the Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder

Sponsor

National Taiwan University Hospital

Enrollment

160 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Metabolomics Methylphenidate

Summary

To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

Eligibility

Min Age: 6 YearsMax Age: 18 Years

Inclusion Criteria6

Patients with ADHD
Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.
At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.
Patients have a Full IQ (FIQ) score greater than 80.
aged 6 to 18 years
All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.

Exclusion Criteria7

Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.
Patients have a major disorder of central nervous system, such as epilepsy.
Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.
Patients have ever received any medication to treat the clinical symptoms of ADHD.
Neurotypical participants:
participants have any disorder of central nervous system or major systemic disease
participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.